A human monoclonal antibody against the collagen type IV α3NC1 domain is a non-invasive optical biomarker for glomerular diseases

Kidney International

Volumn 84, Issue 2, 2013, Pages 403-408

  Chaudhary, Kapil ^a   Kleven, Daniel T ^a   McGaha, Tracy L ^a   Madaio, Michael P ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Biomarkers; Imaging; Nephritis; Renal disease; 3(IV) collagen

Indexed keywords

FLUORESCENT DYE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F1.1; PUROMYCIN AMINONUCLEOSIDE; TUMSTATIN; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FLUORESCENCE IMAGING; GLOMERULUS; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNE COMPLEX NEPHRITIS; IN VIVO STUDY; KIDNEY INJURY; KIDNEY PARENCHYMA; MOUSE; NEPHROSIS; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; SIGNAL DETECTION;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIGENS; BIOLOGICAL MARKERS; CHILD; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; MALE; MICE; MIDDLE AGED; NEPHRITIS; NEPHROSIS; PREDICTIVE VALUE OF TESTS; PROTEIN STRUCTURE, TERTIARY; PUROMYCIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84881160294     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.99     Document Type: Article

References (21)

1. Wu I, Parikh CR. Screening for kidney diseases: older measures versus novel biomarkers. Clin J Am Soc Nephrol 2008; 3: 1895-1901.
2. Varghese SA, Powell TB, Budisavljevic MN et al. Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007; 18: 913-922. (Pubitemid 46434508)
3. Pedchenko V, Bondar O, Fogo AB et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med 2010; 363: 343-354.
4. Hudson BG, Tryggvason K, Sundaramoorthy M et al. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348: 2543-2556. (Pubitemid 36706542)
5. Borza DB, Bondar O, Colon S et al. Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement: novel mechanisms for immune privilege and autoimmune pathogenesis. J Biol Chem 2005; 280: 27147-27154. (Pubitemid 41040753)
6. Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and anti-glomerular basement membrane antibody-mediated disease (Goodpasture's syndrome). Am J Ind Med 1992; 21: 141-153.
7. Kalluri R, Cantley LG, Kerjaschki D et al. Reactive oxygen species expose cryptic epitopes associated with autoimmune goodpasture syndrome. J Biol Chem 2000; 275: 20027-20032. (Pubitemid 30441611)
8. Meyers KE, Christensen M, Madaio MP. Modeling of human anti-GBM antibody-alpha3(IV)NC1 interactions predicts antigenic cross-linking through contact of both heavy chains with repeating epitopes on alpha3(IV)NC1. Am J Nephrol 2009; 30: 474-480.
9. Meyers KE, Allen J, Gehret J et al. Human antiglomerular basement membrane autoantibody disease in XenoMouse II. Kidney Int 2002; 61: 1666-1673. (Pubitemid 34437920)
10. Wang L, Fields TA, Pazmino K et al. Activation of Galpha q-coupled signaling pathways in glomerular podocytes promotes renal injury. J Am Soc Nephrol 2005; 16: 3611-3622. (Pubitemid 46211282)
11. Awad AS, Rouse M, Liu L et al. Activation of adenosine 2A receptors preserves structure and function of podocytes. J Am Soc Nephrol 2008; 19: 59-68.
12. Ahuja TS, Velasco A, Deiss W Jr. et al. Diabetic nephropathy with anti- GBM nephritis. Am J Kidney Dis 1998; 31: 127-130. (Pubitemid 28116694)
13. Basford AW, Lewis J, Dwyer JP et al. Membranous nephropathy with crescents. J Am Soc Nephrol 2011; 22: 1804-1808.
14. Curioni S, Ferrario F, Rastaldi MP et al. Anti-GBM nephritis complicating diabetic nephropathy. J Nephrol 2002; 15: 83-87. (Pubitemid 34240103)
15. Troxell ML, Saxena AB, Kambham N. Concurrent anti-glomerular basement membrane disease and membranous glomerulonephritis: a case report and literature review. Clin Nephrol 2006; 66: 120-127. (Pubitemid 44219438)
16. Clyne S, Frederick C, Arndt F et al. Concurrent and discrete clinicopathological presentations of Wegener granulomatosis and anti-glomerular basement membrane disease. Am J Kidney Dis 2009; 54: 1116-1120.
17. Luo W, Wang XP, Kashtan CE et al. Alport alloantibodies but not Goodpasture autoantibodies induce murine glomerulonephritis: protection by quinary crosslinks locking cryptic alpha3(IV) collagen autoepitopes in vivo. J Immunol 2010; 185: 3520-3528.
18. Gibson MA, Kumaratilake JS, Cleary EG. The protein components of the 12-nanometer microfibrils of elastic and nonelastic tissues. J Biol Chem 1989; 264: 4590-4598. (Pubitemid 19081364)
19. Kaneko Y, Nimmerjahn F, Madaio MP et al. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 2006; 203: 789-797.
20. Shao WH, Zhen Y, Rosenbaum J et al. A protective role of Mer receptor tyrosine kinase in nephrotoxic serum-induced nephritis. Clin Immunol 2010; 136: 236-244.
21. Ravishankar B, Liu H, Shinde R et al. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc Natl Acad Sci USA 2012; 109: 3909-3914.